Persistent nasal methicillin-resistant staphylococcus aureus carriage in hemodialysis outpatients: a predictor of worse outcome

BMC Nephrology

Stephan R Lederer¹  Helmut Schiffl¹  Andre Romanos²  Holger Schmid¹ 

[1]Clinic and Policlinic IV, Section of Nephrology, University of Munich, Munich, Germany

[2]KFH Nierenzentrum Muenchen – Laim, Elsenheimerstr. 36, Munich, 80687, Germany

关键词: Outcome;    Comorbidity;    MRSA;    Staphylococcus aureus;    ESRD;    Hemodialysis;   

Others  :  1082946
DOI  :  10.1186/1471-2369-14-93

 received in 2012-10-30, accepted in 2013-04-17,  发布年份 2013

【 摘 要 】

Background

Nasal colonization with methicillin-resistant Staphylococcus aureus (MRSA) is a well defined risk factor for subsequent bacteremia and death in various groups of patients, but its impact on outcome in patients receiving long-term hemodialysis (HD) is under debate.

Methods

This prospective interventional cohort study (performed 2004 to 2010) enrolled 289 HD outpatients of an urban dialysis-unit. Nasal swab cultures for MRSA were performed in all patients upon first admission, at transfer from another dialysis facility or readmission after hospitalisation. Nasal MRSA carriers were treated in a separate ward and received mupirocin nasal ointment. Concomitant extra-nasal MRSA colonization was treated with 0.2% chlorhexidine mouth rinse (throat) or octenidine dihydrochloride containing antiseptic soaps and 2% chlorhexidine body washes (skin). Clinical data and outcome of carriers and noncarriers were systematically analyzed.

Results

The screening approach identified 34 nasal MRSA carriers (11.7%). Extra-nasal MRSA colonization was observed in 11/34 (32%) nasal MRSA carriers. History of malignancy and an increased Charlson Comorbidity Index were significant predictors for nasal MRSA carriers, whereas traditional risk factors for MRSA colonization or markers of inflammation or malnutrition were not able to discriminate. Kaplan-Meier analysis demonstrated significant survival differences between MRSA carriers and noncarriers. Mupirocin ointment persistently eliminated nasal MRSA colonization in 26/34 (73.5%) patients. Persistent nasal MRSA carriers with failure of this eradication approach had an extremely poor prognosis with an all-cause mortality rate >85%.

Conclusions

Nasal MRSA carriage with failure of mupirocin decolonization was associated with increased mortality despite a lack of overt clinical signs of infection. Further studies are needed to demonstrate whether nasal MRSA colonization represents a novel predictor of worse outcome or just another surrogate marker of the burden of comorbid diseases leading to fatal outcome in HD patients.

【 授权许可】

   
2013 Schmid et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 6.

Figure 4.

【 参考文献 】

• [1]Himmelfarb J, Ikizler TA: Hemodialysis. N Engl J Med 2010, 363(19):1833-1845.
• [2]Vandecasteele SJ, Boelaert JR, De Vriese AS: Staphylococcus aureus infections in hemodialysis: what a nephrologist should know. Clin J Am Soc Nephrol 2009, 4(8):1388-1400.
• [3]Johnson LB, Jose J, Yousif F, Pawlak J, Saravolatz LD: Prevalence of colonization with community-associated methicillin-resistant Staphylococcus aureus among end-stage renal disease patients and healthcare workers. Infect Control Hosp Epidemiol 2009, 30(1):4-8.
• [4]Nori US, Manoharan A, Thornby JI, Yee J, Parasuraman R, Ramanathan V: Mortality risk factors in chronic haemodialysis patients with infective endocarditis. Nephrol Dial Transplant 2006, 21(8):2184-2190.
• [5]Fitzgibbons LN, Puls DL, Mackay K, Forrest GN: Management of gram-positive coccal bacteremia and hemodialysis. Am J Kidney Dis 2011, 57(4):624-640.
• [6]del Rio A, Cervera C, Moreno A, Moreillon P, Miró JM: Patients at risk of complications of Staphylococcus aureus bloodstream infection. Clin Infect Dis 2009, 48(Suppl 4):S246-S253.
• [7]Parker MG, Doebbeling BN: The challenge of methicillin-resistant Staphylococcus aureus prevention in hemodialysis therapy. Semin Dial 2012, 25(1):42-49.
• [8]Lai CF, Liao CH, Pai MF, Chu FY, Hsu SP, Chen HY, Yang JY, Chiu YL, Peng YS, Chang SC, Hung KY, Tsai TJ, Wu KD: Nasal carriage of methicillin-resistant Staphylococcus aureus is associated with higher all-cause mortality in hemodialysis patients. Clin J Am Soc Nephrol 2011, 6(1):167-174.
• [9]Baillargeon J, Kelley MF, Leach CT, Baillargeon G, Pollock BH: Methicillin-resistant Staphylococcus aureus infection in the Texas prison system. Clin Infect Dis 2004, 38(9):e92-e95.
• [10]Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40(5):373-383.
• [11]Calfee DP: The epidemiology, treatment, and prevention of transmission of methicillin-resistant Staphylococcus aureus. J Infus Nurs 2011, 34(6):359-364.
• [12]Lederer SR, Riedelsdorf G, Schiffl H: Nasal carriage of meticillin resistant Staphylococcus aureus: the prevalence, patients at risk and the effect of elimination on outcomes among outclinic haemodialysis patients. Eur J Med Res 2007, 12(7):284-288.
• [13]Buehlmann M, Frei R, Fenner L, Dangel M, Fluckiger U, Widmer AF: Highly effective regimen for decolonization of methicillin-resistant Staphylococcus aureus carriers. Infect Control Hosp Epidemiol 2008, 29(6):510-516.
• [14]Krishna BV, Gibb AP: Use of octenidine dihydrochloride in meticillin-resistant Staphylococcus aureus decolonisation regimens: a literature review. J Hosp Infect 2010, 74(3):199-203.
• [15]Fluck R, Wilson J, Tomson CR: UK Renal Registry 12th Annual Report (December 2009): chapter 12: epidemiology of methicillin resistant Staphylococcus aureus bacteraemia amongst patients receiving dialysis for established renal failure in England in 2008: a joint report from the UK Renal Registry and the Health Protection Agency. Nephron Clin Pract 2010, 115(Suppl 1):c261-c270.
• [16]Dulon M, Haamann F, Peters C, Schablon A, Nienhaus A: MRSA prevalence in European healthcare settings: a review. BMC Infect Dis 2011, 11:138. BioMed Central Full Text
• [17]Köseoğlu O, Sayın Kutlu S, Cevahir N: Prevalence and risk factors for methicillin-resistant Staphylococcus aureus colonization among outpatients undergoing hemodialysis treatment. Mikrobiyol Bul 2012, 46(1):106-112.
• [18]Patel G, Jenkins SG, Mediavilla JR, Kreiswirth BN, Radbill B, Salgado CD, Calfee DP: Clinical and molecular epidemiology of methicillin-resistant Staphylococcus aureus among patients in an ambulatory hemodialysis center. Infect Control Hosp Epidemiol 2011, 32(9):881-888.
• [19]Hadley AC, Karchmer TB, Russell GB, McBride DG, Freedman BI: The prevalence of resistant bacterial colonization in chronic hemodialysis patients. Am J Nephrol 2007, 27(4):352-359.
• [20]Wang CY, Wu VC, Wang WJ, Lin YF, Lin YH, Chen YM, Su CT, Wang JY, Wu KD, Hsueh PR: Risk factors for nasal carriage of methicillin-resistant Staphylococcus aureus among patients with end-stage renal disease in Taiwan. J Formos Med Assoc 2012, 111(1):14-18.
• [21]Celik G, Gülcan A, Dikici N, Gülcan E: Prevalence of nasal Staphylococcus aureus carriage in the patients undergoing hemodialysis and evaluation of risk factors and laboratory parameters. Ren Fail 2011, 33(5):494-498.
• [22]Cookson B, Bonten MJ, Mackenzie FM, Skov RL, Verbrugh HA, Tacconelli E: European society of clinical microbiology and infectious diseases (ESCMID); international society of chemotherapy (ISC). meticillin-resistant staphylococcus aureus (MRSA): screening and decolonisation. Int J Antimicrob Agents 2011, 37(3):195-201.
• [23]Simor AE: Staphylococcal decolonisation: an effective strategy for prevention of infection? Lancet Infect Dis 2011, 11(12):952-962.
• [24]Hebert C, Robicsek A: Decolonization therapy in infection control. Curr Opin Infect Dis 2010, 23(4):340-345.
• [25]McKinnell JA, Huang SS, Eells SJ, Cui E, Miller LG: Quantifying the impact of extranasal testing of body sites for methicillin-resistant Staphylococcus aureus colonization at the time of hospital or intensive care unit admission. Infect Control Hosp Epidemiol 2013, 34(2):161-170.
• [26]Laupland KB, Ross T, Gregson DB: Staphylococcus aureus bloodstream infections: risk factors, outcomes, and the influence of methicillin resistance in Calgary, Canada, 2000–2006. J Infect Dis 2008, 198(3):336-343.
• [27]Lessa FC, Mu Y, Ray SM, Dumyati G, Bulens S, Gorwitz RJ, Fosheim G, DeVries AS, Schaffner W, Nadle J, Gershman K, Fridkin SK, Active Bacterial Core surveillance (ABCs): Impact of USA300 methicillin-resistant Staphylococcus aureus on clinical outcomes of patients with pneumonia or central line-associated bloodstream infections. Clin Infect Dis 2012, 55(2):232-241.
• [28]Bader MS: Staphylococcus aureus bacteremia in older adults: predictors of 7-day mortality and infection with a methicillin-resistant strain. Infect Control Hosp Epidemiol 2006, 27(11):1219-1225.
• [29]García-García JA, Santos-Morano J, Castro C, Bayoll-Serradilla E, Martín-Ponce ML, Vergara-López S, Martín-Rodríguez LM, Mateos-Gómez A, de la Cueva J, Martín-Mazuelos E, Gómez-Mateos JM, Corzo-Delgado JE: Prevalence and risk factors of methicillin-resistant Staphylococcus aureus colonization among residents living in long-term care facilities in southern Spain. Enferm Infecc Microbiol Clin 2011, 29(6):405-410.
• [30]Centers for Disease Control and Prevention (CDC): Invasive methicillin-resistant Staphylococcus aureus infections among dialysis patients--United States, 2005. MMWR Morb Mortal Wkly Rep 2007, 56(9):197-199.
• [31]Patel M, Weinheimer JD, Waites KB, Baddley JW: Active surveillance to determine the impact of methicillin-resistant Staphylococcus aureus colonization on patients in intensive care units of a Veterans Affairs Medical Center. Infect Control Hosp Epidemiol 2008, 29(6):503-509.
• [32]Luteijn JM, Hubben GA, Pechlivanoglou P, Bonten MJ, Postma MJ: Diagnostic accuracy of culture-based and PCR-based detection tests for methicillin-resistant Staphylococcus aureus: a meta-analysis. Clin Microbiol Infect 2011, 17(2):146-154.
• [33]Johnson LB, Venugopal AA, Pawlak J, Saravolatz LD: Emergence of community-associated methicillin-resistant Staphylococcus aureus infection among patients with end-stage renal disease. Infect Control Hosp Epidemiol 2006, 10:1057-1062.
• [34]Wu HS, Kuo SC, Chen LY, Chiang MC, Lin YT, Wang FD, Fung CP: Comparison between patients under hemodialysis with community-onset bacteremia caused by community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus strains. J Microbiol Immunol Infect 2012, 46(2):96-103.
• [35]O’Sullivan MV, Zhou F, Sintchenko V, Gilbert GL: Prospective genotyping of hospital-acquired methicillin-resistant Staphylococcus aureus isolates by use of a novel, highly discriminatory binary typing system. J Clin Microbiol 2012, 50(11):3513-9.
• [36]Patel JB, Gorwitz RJ, Jernigan JA: Mupirocin resistance. Clin Infect Dis 2009, 49(6):935-41.
• [37]Caffrey AR, Woodmansee SB, Crandall N, Tibert C, Fielding C, Mikolich DJ, Vezeridis MP, LaPlante KL: Low adherence to outpatient preoperative methicillin-resistant Staphylococcus aureus decolonization therapy. Infect Control Hosp Epidemiol 2011, 32(9):930-2.
• [38]McGregor JC, Kim PW, Perencevich EN, Bradham DD, Furuno JP, Kaye KS, Fink JC, Langenberg P, Roghmann MC, Harris AD: Utility of the chronic disease score and Charlson Comorbidity index as comorbidity measures for use in epidemiologic studies of antibiotic-resistant organisms. Am J Epidemiol 2005, 161(5):483-93.
• [39]Dalrymple LS, Mohammed SM, Mu Y, Johansen KL, Chertow GM, Grimes B, Kaysen GA, Nguyen DV: Risk of cardiovascular events after infection-related hospitalizations in older patients on dialysis. Clin J Am Soc Nephrol 2011, 6(7):1708-13.